---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-237729"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:27:44.324106+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Puma Biotech Q2 2021 GAAP net loss $5.1M vs prior-year profit; NERLYNX flat at $48.9M

## Summary
- GAAP net loss of $5.1M ($0.13 loss/share) vs net income of $3.4M in Q2 2020.
- Non-GAAP adjusted net income $13.1M ($0.32/share) vs $14.0M ($0.36/share) in Q2 2020.
- NERLYNX net revenue $48.9M, essentially flat vs $48.8M in Q2 2020.
- Cash & securities $108.9M at June 30, 2021, up from $93.4M at Dec 31, 2020.
- Received label expansion for NERLYNX dose escalation; SUMMIT top-line data expected Q4 2021.

## SEC filing metadata
- accession: 0001193125-21-237729
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/0001193125-21-237729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000119312521237729/d212533d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-237729
- JSON: https://secwatch.observer/filing/0001193125-21-237729.json
- Plain text: https://secwatch.observer/filing/0001193125-21-237729.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.